Introduction
Abnormalities of glucose tolerance and fasting lipid levels are present singly or in combination in a major proportion of patients suffering from ischaemic heart disease (Carlson & Wahlberg, 1966) and peripheral vascular disease (Bliss, Kirk & Newall, 1972) .
It is currently fashionable to treat lipid abnormalities by diet (Frederickson et al., 1970) or with various lipid-lowering agents (Strisower, Adamson & Strisower, 1968) , although the effectiveness of such therapy in preventing deterioration of the vascular lesions has yet to be demonstrated.
Treatment of the abnormalities of glucose tolerance is also undergoing trial and the use of tolbutamide has met with some measure of success (Keen et al., 1968; Paasikivi, 1970) .
Fenfluramine has been shown to increase muscle uptake of glucose (Butterfield & Whichelow, 1968) . In young healthy adults it promotes fat mobilization, decreasing triglycerides and increasing non-esterified fatty acid levels (Pawan, 1969) . It might, therefore, be expected to reduce or reverse some of the biochemical abnormalities found in atherosclerosis.
This report describes the results of a trial to determine the effect of fenfluramine on glucose tolerance, (Bliss et al., 1972) are as follows:
(1) Fasting blood glucose-normal <90 mg/100 ml; borderline 90-100 mg/100 ml; abnormal> 100 mg/100 ml.
(2) K glucose-normal> 1 4; abnormal < 1 0.
(3) 60 min blood glucose-normal <110 mg/100 ml; abnormal> 130 mg/100 ml.
(4) Insulin-normal 4-30 ,u units/ml; abnormal > 30 ,u units/mi.
(5) NEFA-normal <09 mEq/l; abnormal> 1.0 mEq/l.
(6) Cho!esterol-normal <250 mg/100 ml; abnormal> 270 mg/100 ml.
(7) Glyceride glycerol-normal <18 mg/100 ml; abnormal> 20 mg/100 ml.
(8) Lipoproteins-using the arbitrary units of Stone & Thorp (1966) (1) Glucose tolerance
The effect of the 6-week course of fenfluramine on fasting blood glucose, K glucose and 60-min blood glucose levels is shown in Table 1 .
Most of the patients demonstrated an increase in glucose utilization as shown by a reduction in fasting glucose levels, an increase in K glucose and a decrease in the 60-min glucose levels. When the mean levels of each parameter in the pre-and post-treatment tests are compared these changes are statistically significant in each case. The values for P are shown in the The effects of the 6-week course of fenfluramine on the fasting insulin, and also on the peak and 60-min insulin levels after intravenous glucose, are shown in Table 2 .
In some patients insulin levels are increased and in others decreased, without any consistent pattern. There is no statistically significant difference between mean levels of insulin in the pre-treatment and posttreatment tests.
(3) Fasting lipid levels
The effects of the 6-week course of fenfluramine on fasting levels of NEFA, cholesterol, glyceride glycerol, 3 and pre-3 lipoproteins are shown in Table 3 .
There is no significant difference in NEFA, glyceride glycerol and pre-,3 lipoproteins in the preand post-fenfluramine periods.
There is, however, a small, but statistically significant, reduction in the cholesterol and b lipoprotein levels following treatment.
In Table 4 the effect of fenfluramine on patients with abnormal pretreatment levels of fasting cholesterol and ,3 lipoprotein is shown. Again the effects are greater in this group than for the series as a whole. There were nine such patients. Seven showed a fall in cholesterol levels, with a mean reduction of 47 mg/ 100 ml, and six a fall in ,3 lipoproteins with a mean reduction of 0.7 unit. In four of these patients the reduction in fasting cholesterol and in five the reduction in fasting (3 lipoproteins was sufficient to bring the post-treatment level into the borderline or normal range:
Evaluation of the results in patients with abnormal pre-treatment levels of NEFA, glyceride glycerol and pre-(3 lipoproteins did not alter the findings described for the series as a whole.
Weight changes
Since fenfluramine is currently marketed as an anti-obesity agent some variation in weight following the course of treatment might be expected, although we instructed our patients to maintain a normal diet. When pre-and post-treatment weighings are compared, however, most patients show only small variations with increases or decreases of -1 lb.
Three patients lost significant amounts of weight-4, 5 and 10 lb respectively, whilst the weight of one patient increased by 21 lb. Diarrhoea as a side-effect did not seemn to influence the weight changes.
Discussion
In a series of twenty-five patients suffering from peripheral arterial disease the effects of fenfluramine were significantly to improve glucose tolerance and reduce the fasting cholesterol and 3 lipoprotein levels. There was no significant change in nonesterified fatty acid, glyceride glycerol or pre-3 lipoproteins, nor in insulin levels. The changes brought about by fenfluramine therapy could be seen whether or not the patients had abnormal pre-treatment levels but were more marked in the former group.
Since there was no change in fasting insulin nor in insulin secretion following intravenous glucose, it would seem that the changes in glucose tolerance were not mediated through changes in insulin. This would support the findings of Butterfield & Whichelow (1968) that fenfluramine acts to increase muscle uptake of glucose. Since insulin has been implicated as a possible causative agent in atherosclerosis (Stout & Vallance-Owen, 1969) there may be some doubt regarding the use of agents which improve glucose tolerance by increasing insulin levels, such as the sulphonylurea group of drugs, despite the favourable findings of Paasikivi (1970) using tolbutamide. In this context the effectiveness of fenfluramine in improving glucose tolerance without raising insulin levels may be important.
The improvement in glucose tolerance could be due to weight reduction but this did not appear to be the case in our series since only three patients lost significant amounts of weight. Furthermore VallanceOwen (1971) believes that the improvement in glucose tolerance in obese patients treated by dietary restriction is due to reduction of carbohydrate intake rather than to loss of weight. Our patients were instructed to maintain a normal diet during fenfluramine therapy. Pawan (1969) in a group of healthy young adults found that fenfluramine reduced fasting triglyceride levels, increased fasting NEFA levels but had no effect on cholesterol. It was therefore surprising to find that in this group of patients with peripheral arterial disease fenfluramine produced no consistent effect on fasting NEFA, glyceride or pre-53 lipoprotein levels. Conversely, a significant reduction of fasting cholesterol and 3 lipoprotein levels resulted in most cases. Apart from the presence of arterial disease the reason for this discrepancy in the effect of fenfluramine is not apparent.
The effect of fenfluramine on fasting cholesterol levels and on 3 lipoproteins was small. Although in some patients the abnormality was corrected into the normal range it is unlikely that the degree of reduction will be sufficient to help most patients suffering from hypercholesterolaemia. Fenfluramine may, however, prove to be a useful adjunct, especially when the lipid abnormality is associated with impaired glucose tolerance, as is the case in many of these patients (Bliss, 1971) .
